Trial Profile
A Phase 1, open label, dose escalation study of the safety, tolerability and preliminary efficacy of intraperitoneal EGEN-001 in patients with recurrent epithelial ovarian cancer.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs IMNN 001 (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions
- 27 Feb 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 13 Jul 2007 New trial record.